Scholar Rock Quarterly Income Statement
NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
42.19-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Scholar Rock revenue and earnings
In the quarter ended Jun 30, 2026, Scholar Rock generated $0 in revenue. Scholar Rock reported a net loss of $109.9 million, compared with a loss of $110.0 million a year earlier. Diluted earnings per share came in at -$0.84.
Summary generated from market data by MetaCap's automated system. Methodology
Scholar Rock income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 108.90M | 102.02M | 91.90M | 103.55M | 112.11M | 77.09M | 69.36M | 64.78M | 59.50M | 58.42M | 48.03M | 43.67M |
| Research & Development | 58.23M | 51.81M | 46.88M | 50.49M | 62.40M | 48.68M | 50.37M | 48.72M | 42.37M | 43.09M | 34.96M | 30.34M |
| Operating Income | -108.90M | -102.02M | -91.90M | -103.55M | -112.11M | -77.09M | -69.36M | -64.78M | -59.50M | -58.42M | -48.03M | -43.67M |
| Interest Expense | 4.52M | 2.30M | 2.53M | 1.33M | 1.21M | 1.82M | 1.65M | 1.74M | 1.72M | — | — | — |
| Other Income (Expense) | -995.00K | -3.49M | 931.00K | 1.33M | 2.08M | 2.37M | 2.90M | 301.00K | 990.00K | 1.57M | 1.91M | 1.31M |
| Net Income | -109.90M | -105.51M | -90.97M | -102.22M | -110.03M | -74.72M | -66.45M | -64.48M | -58.51M | -56.85M | -46.13M | -42.36M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.84 | -0.83 | -0.74 | -0.90 | -0.98 | -0.67 | -0.62 | -0.66 | -0.60 | -0.59 | -0.50 | -0.53 |
| EPS (Diluted) | -0.84 | -0.83 | -0.74 | -0.90 | -0.98 | -0.67 | -0.62 | -0.66 | -0.60 | -0.59 | -0.50 | -0.53 |
| Shares Outstanding (Basic) | 130.61M | 127.28M | — | 113.73M | 112.70M | 111.84M | — | 97.05M | 96.81M | 95.89M | — | 80.61M |
| Shares Outstanding (Diluted) | 130.61M | 127.28M | — | 113.73M | 112.70M | 111.84M | — | 97.05M | 96.81M | 95.89M | — | 80.61M |
| EBITDA | -108.60M | -101.68M | -91.47M | -103.13M | -111.69M | -76.70M | -68.96M | -64.33M | -59.00M | -57.82M | -47.36M | -42.96M |
This table shows 12 quarterly periods of Scholar Rock's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SRRK's reporting calendar. What is a income statement?